Nicotine suppresses lipopolysaccharide-induced release of interleukin-6 in mixed glia and microglia-enriched cultures

Neural Regeneration Research

Volumn 6, Issue 5, 2011, Pages 325-329

  Li, Zhihua ^a   Zhao, Qingzan ^a   Zhang, Hua ^a   Ren, Xiuhua ^a   Zhou, Mingfu ^a   Zang, Weidong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cytokine; Glia; Lipopolysaccharides; Nicotine; Parkinson's disease

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NICOTINE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GLIA; IN VITRO STUDY; INFLAMMATION; MALE; MICROGLIA; MIXED CELL CULTURE; NERVE CELL CULTURE; NEUROPROTECTION; NEWBORN; NONHUMAN; RAT; SIGNAL TRANSDUCTION;

EID: 79952467950     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004;27:561-568.
2. Chapman MA. Does smoking reduce the risk of Parkinson's disease through stimulation of the ubiquitin-proteasome system? Med Hypotheses. 2009;73(6):887-891.
3. Kas A, Bottlaender M, Gallezot JD, et al. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab. 2009;29(9):1601-1608.
4. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol. 2003;53(Suppl 3):49-60.
5. Barcia C, Ros F, Carrillo MA, et al. Inflammatory response in Parkinsonism. J Neural Transm Suppl. 2009;(73):245-252.
6. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57(2):168-175.
7. Mcgeer PL, Yasojima K, Mcgeer EG. Inflammation in Parkinon's disease. Adv Neurol. 2001;86:83-89.
8. Wilms H, Zecca L, Rosenstiel P, et al. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des. 2007;13(18):1925-1928.
9. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl. 2006;(70):373-381.
10. Wenning GK, Stefanova N, Jellinger KA, et al. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol. 2008;64(3): 239-246.
11. Pivneva TA. Microglia in normal condition and pathology. Fiziol Zh 2008;54(5):81-89.
12. Verkhratsky A, Olabarria M, Noristani HN, et al. Astrocytes in Alzheimer's disease. Neurotherapeutics. 2010;7(4):399-412.
13. Le W, Rowe D, Xie W, et al. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci. 2001;21(21):8447-8455.
14. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 2007;35(Pt 5): 1127-1132.
15. Hinkerohe D, Smikalla D, Haghikia A, et al. Effects of cytokines on microglial phenotypes and astroglial coupling in an inflammatory coculture model. Glia. 2005;52(2):85-97.
16. Imamura K, Hishikawa N, Ono K, et al. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol. 2005;109(2):141-150.
17. Ishida Y, Nagai A, Kobayashi S, et al. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol. 2006;65(1): 66-77.
18. Herrera AJ, Castano A, Venero JL, et al. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000;7:429-447.
19. Arai H, Furuya T, Yasuda T, et al. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J Biol Chem. 2004;279(49):51647-51653.
20. Klegeris A, Walker DG, McGeer PL. Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology. 1999; 38:1017-1025.
21. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol. 2002;8: 529-538.
22. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639-647.
23. Wahner AD, Sinsheimer JS, Bronstein JM, et al. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol. 2007;64(6):836-840.
24. Nagatsu T, Mogi M, Ichinose H, et al. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl. 2000;(60):277-290.
25. Xu Y, Xue Y, Wang Y, et al. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol. 2009;9(3):360-365.
26. Lee M, Sparatore A, Del Soldato P, et al. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia. 2010;58(1):103-113.
27. Wilms H, Sievers J, Rickert U, et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010;7:30.
28. Li ZH, Fan JX, Ren XH, et al. Nicotine suppress LPS-induced microglia activation and degeneration of dopaminergic neurons. Jiepou Xue Zazhi. 2010;33(4):492-494.
29. Hwang J, Zheng LT, Ock J, et al. Anti-inflammatory effects of m-chlorophenylpiperazine in brain glia cells. Int Immunopharmacol. 2008;8(12):1686-1694.
30. Zheng LT, Hwang J, Ock J, et al. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J Neurochem. 2008;107(5):1225-1235.
31. Zheng LT, Ock J, Kwon BM, et al. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol. 2008;8(3):484-494.
32. Zheng LT, Ryu GM, Kwon BM, et al. Anti-inflammatory effects of catechols in lipopolysaccharide-stimulated microglia cells: inhibition of microglial neurotoxicity. Eur J Pharmacol. 2008; 588(1):106-113.
33. Long-Smith CM, Collins L, Toulouse A, et al. Interleukin-1β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro. J Neuroimmunol. 2010;226(1-2):20-26.
34. Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther. 2000;293:607-617.
35. Li XZ, Bai LM, Yang Y P, et al. Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced inflammation. Neurosci Res. 2009; 65(3):252-258.
36. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85(3):890-902.
37. Saura J. Microglial cells in astroglial cultures: a cautionary note. J Neuroinflammation. 2007;4:26.
38. Kong LY, Lai C, Wilson BC, et al. Protein tyrosine kinase inhibitors decrease lipopolysaccharide-induced proinflammatory cytokine production in mixed glia, microglia-enriched or astrocyte-enriched cultures. Neurochem Int. 1997;30(4-5):491-497.
39. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol. 2007;150:963-976.